Prema Maria Mertz

Array ( [id] => 19060165 [patent_doc_number] => 11939374 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Treatment of fibrosis [patent_app_type] => utility [patent_app_number] => 17/110094 [patent_app_country] => US [patent_app_date] => 2020-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 106 [patent_no_of_words] => 33394 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17110094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19368331 [patent_doc_number] => 12060401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders [patent_app_type] => utility [patent_app_number] => 17/106493 [patent_app_country] => US [patent_app_date] => 2020-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 42 [patent_no_of_words] => 30722 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17106493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885445 [patent_doc_number] => 20210171640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => ANTI-VISTA ANTIBODIES AND FRAGMENTS, USES THEREOF, AND METHODS OF IDENTIFYING SAME [patent_app_type] => utility [patent_app_number] => 17/104287 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29118 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17104287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170421 [patent_doc_number] => 20210324091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => CD131 BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/953499 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16953499 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16870098 [patent_doc_number] => 20210163565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => CYTOKINE FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS [patent_app_type] => utility [patent_app_number] => 16/952079 [patent_app_country] => US [patent_app_date] => 2020-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39143 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16952079 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18034692 [patent_doc_number] => 20220378907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => METHODS FOR TREATING DISEASES [patent_app_type] => utility [patent_app_number] => 17/755787 [patent_app_country] => US [patent_app_date] => 2020-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17755787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688352 [patent_doc_number] => 20210070828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 17/091190 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15803 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18034676 [patent_doc_number] => 20220378891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => METHODS AND COMPOSITIONS FOR USE OF GROWTH FACTOR ANTIBODIES IN COMBINATION WITH NON-TYROSINE TARGETING KINASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/773741 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17773741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036235 [patent_doc_number] => 20220380450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => METHODS OF USING IL-33 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/755605 [patent_app_country] => US [patent_app_date] => 2020-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25678 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -72 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17755605 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18177093 [patent_doc_number] => 20230037822 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => IMMUNE CELL RECEPTOR ANTIBODIES CONJUGATED TO HIGH AFFINITY SIGLEC-LIGANDS [patent_app_type] => utility [patent_app_number] => 17/755382 [patent_app_country] => US [patent_app_date] => 2020-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17755382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762417 [patent_doc_number] => 20210107998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => COMPOUND TARGETING IL-23A AND B-CELL ACTIVATING FACTOR (BAFF) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/076894 [patent_app_country] => US [patent_app_date] => 2020-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932466 [patent_doc_number] => 20210198355 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => ANTI-IL-23 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/066994 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17066994 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20555415 [patent_doc_number] => 20260055195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-26 [patent_title] => TARGETING EPHA3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/781271 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26466 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17781271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824261 [patent_doc_number] => 20210139554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS [patent_app_type] => utility [patent_app_number] => 17/065395 [patent_app_country] => US [patent_app_date] => 2020-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28574 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -125 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17065395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727850 [patent_doc_number] => 20210094997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS [patent_app_type] => utility [patent_app_number] => 17/063566 [patent_app_country] => US [patent_app_date] => 2020-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18685195 [patent_doc_number] => 11780913 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => IL-1b neutralizing human monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 17/061194 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 17 [patent_no_of_words] => 10130 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17061194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18492272 [patent_doc_number] => 11697683 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-11 [patent_title] => Anti-IL31 antibodies for veterinary use [patent_app_type] => utility [patent_app_number] => 17/039495 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 13 [patent_no_of_words] => 16300 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18004987 [patent_doc_number] => 20220363753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => ANTI-TIRC7 ANTIGEN BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 17/765267 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413173 [patent_doc_number] => 11667706 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Methods of purifying recombinant anti-abeta antibodies [patent_app_type] => utility [patent_app_number] => 17/031468 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 7 [patent_no_of_words] => 36782 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17031468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958677 [patent_doc_number] => 20220339257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => METHODS TO INCREASE THE SENSITIVITY AND REVERSING THE RESISTANCE TO DRUGS [patent_app_type] => utility [patent_app_number] => 17/761461 [patent_app_country] => US [patent_app_date] => 2020-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14872 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761461 [rel_patent_id] =>[rel_patent_doc_number] =>)